Global Health Limited September 2024 Quarterly Activities Report and Appendix 4C

Global Health Limited (ASX: GLH) unveiled its impressive Appendix 4C Cash Flow Report for the quarter ended 30 September 2024, alongside the Quarterly Business Activity Report. In Q1 FY25, the company's performance showed remarkable growth compared to the Previous Corresponding Period of Q1 FY24. Key highlights include a 13% increase in Annual Recurring Revenue, a 13% rise in cash receipts, a 14% reduction in net operating and investing cashflow from the PCP, and a 28% decrease in the Group Cashflow deficit from the PCP. Notably, during Q1 FY25, the Annual Recurring Revenue surged to AU$1.71 million, reflecting an impressive 11.62% increase from the previous quarter and a substantial 13% jump from the PCP. This remarkable growth in ARR not only underlines the company's potential but also provides compelling reasons for optimism about its future.

Further, it highlights a significant one-off expense incurred due to the transition of its Data Centre from Macquarie Telecom to Microsoft Azure, involving payments exceeding AU$200,000. This transition also entailed professional services expenses and a doubling of hosting costs as the company paid hosting fees to both parties during the transition. As a result, the platforms achieved compliance and secured listings on the Microsoft marketplace globally.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com